A Pill for Type 1 Diabetes? Two New Studies Investigate SGLT-2 Inhibitor Jardiance
Twitter Summary: Trials assess the safety and effectiveness of SGLT-2 inhibitor empagliflozin (Jardiance)
We’re bringing you a double trial watch — two clinical studies assessing the safety and effectiveness of the pill Jardiance (aka empagliflozin, an SGLT-2 inhibitor) in adults with type 1 diabetes. SGLT-2 inhibitors work by causing the kidneys to excrete excess glucose through the urine; they are a unique drug class in that they work independently of insulin.
Why is this new/important:
Jardiance is currently approved in the US for type 2 diabetes, but not type 1. These phase 3 studies are collecting additional data on the safety and effectiveness of Jardiance for type 1 diabetes. There has been a lot of excitement around Jardiance due to the recent groundbreaking evidence that it can reduce heart failure and death from heart disease for people with type 2 diabetes at high risk for heart disease. While it is not known whether these benefits apply to people with type 1 diabetes, the potential for A1c reductions, weight loss, lower blood pressure, and flatter glucose profiles could make the drug an appealing option for many people. Indeed, some people with type 1 diabetes already take Jardiance or other SGLT-2 inhibitors “off-label,” though this is generally not recommended due to the lack of safety information available. The advantage of SGLT-2 inhibitors is that they are glycemic dependent – that means they cause the user to urinate excess glucose when blood sugars are high, but they stop working when blood sugars are low. A major goal of these studies is to see how the benefits mentioned above stack up against risks like diabetic ketoacidosis, which may be a concern with this drug class in type 1 diabetes.
The main difference between the two studies is trial length. You can find information on both trials below.
26-WEEK TRIAL
Clinical Trial Identifier: NCT02580591
Trial name: Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients with T1DM (EASE-3)
Diabetes type: Type 1 diabetes
What it’s testing: This trial will assess the efficacy, safety, tolerability, and pharmacokinetics (how a drug is metabolized by the body) of three doses of Jardiance as a supplement to insulin in people with type 1 diabetes.
Trial participants will receive a low, medium or high dose of Jardiance once-daily for 26 weeks, while continuing use of insulin multiple daily injections (MDI) or an insulin pump.
What the trial is measuring: This study is primarily focused on change in A1c, as well as other outcomes such as percent time spent in a target glucose range (70-180 mg/dl), and rates of hypoglycemia. More details here.
Trial Length: 26 weeks
Trial Location: The trial is currently recruiting in the following US states: CA, GA, MD, and TN. For a full list of current and future locations (including several European locations, Canada, and Australia), see here.
Do you qualify?
-
18+ years old
-
Type 1 diabetes and used insulin for at least one year
-
A1c of 7.5% to 10%
-
Administering insulin via multiple daily injections (MDI) or insulin pump user with total daily insulin between 0.3 and 1.5 units per kilogram
-
Body Mass Index (BMI) greater than 18.5 (Calculate your BMI here)
Exclusion criteria include:
-
A history of type 2 diabetes
-
Past treatment for type 1 diabetes with any other glucose-lowering drug except basal and bolus insulin during the last three months
-
Severe hypoglycemia or diabetic ketoacidosis in the past three months
For a full list of inclusion and exclusion criteria see here.
Where to get more information: For more information, please go to the trial’s webpage and view the contact information specific to each enrolling location.
52-WEEK TRIAL:
Clinical Trial Identifier: NCT02414958
Trial name: Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes Over 52 Weeks (EASE-2)
Diabetes type: Type 1 diabetes
What it’s testing: This trial will assess the efficacy, safety, and tolerability of two doses of Jardiance in people with type 1 diabetes already on a multiple daily injection (MDI) insulin regimen.
Trial participants will receive a high or low dose of Jardiance once daily for 52 weeks, while continuing use of multiple daily injections (MDI) or an insulin pump.
What the trial is measuring: This study is primarily focused on change in A1c, as well as other outcomes such as percent time spent in a target glucose range (70-180 mg/dl), and rates of hypoglycemia. More details here.
Trial Length: 52 weeks
Trial Location: The trial is currently recruiting in the following US states: CA, CO, FL, GA, ID, IL, IA, NE, NV, NH, NY, NC, OH, SD, TN, TX, UT, WA. For a full list of current and future locations, see here.
Do you qualify?
-
18+ years old
-
Type 1 diabetes and used insulin for at least one year
-
A1c of 7.5% to 10%
-
Administering insulin via multiple daily injections (MDI) or insulin pump for the past five months
Exclusion criteria include:
-
A history of type 2 diabetes
-
Past treatment for type 1 diabetes with any other glucose-lowering drug except basal and bolus insulin during the last three months
-
Severe hypoglycemia or diabetic ketoacidosis in the past three months
For a full list of inclusion and exclusion criteria see here.
Where to get more information: For more information, please go to the trial’s webpage and view the contact information specific to each enrolling location. -CA